In:
Cancer Research, American Association for Cancer Research (AACR), Vol. 74, No. 20_Supplement ( 2014-10-15), p. A16-A16
Abstract:
Introduction: Pediatric rhabdomyosarcoma (RMS) has varying outcomes, especially in patients with intermediate-risk disease (IR-RMS), due to the inherent inability of clinical staging to accurately risk-stratify a large proportion of patients. This study aimed to identify prognostic signatures in IR-RMS patients, the clinical subgroup with the most heterogeneous outcomes, which reflect underlying tumor biology and provide better risk stratification than routine clinicopathologic parameters. Signature performance was further validated on an independent set of RMS patients. Methods: Prospectively-obtained primary tumors from 80 IR-RMS patients on Children's Oncology Group clinical trial protocols formed the training set. Tumors from 19, 15 and 20 patients with low-risk, high-risk and IR-RMS formed the validation set. All patients underwent whole transcriptome expression profiling using Affymetrix Human Exon microarrays. Expressions of nearly 1.4 million probe selection regions (PSRs) representing annotated and unannotated transcripts were analyzed. Cox regression and leave-n-out cross validation were used to derive and finalize the weighted signatures. Potentials of the coding and non-coding signatures to predict overall survival were compared using areas under receiver operating characteristic curves that provided a measure of predictive accuracy. Associated biological processes were analyzed using curated pathway analysis tools. Results: Standard pathologic prognosticators such as histologic subtype and PAX-FKHR fusion status were unable to predict survival in the subset of IR-RMS that comprised the training set (p=0.94 and 0.66, respectively). Tumor site was the only clinical predictor of outcome in the training set (p=0.041). Iterative Cox regression on over 17,000 coding transcripts identified a 30-gene meta-feature (30gMF) that was able to predict survival in the training set (p=0.001). Analysis of PSRs corresponding to unannotated transcripts identified a 39-PSR meta-feature (39ncMF) that also predicted survival in the training set (p & lt;0.001). To eliminate feature redundancy, multiple PSRs interrogating the same unannotated genomic locus were replaced by a representative PSR that reduced the non-coding meta-feature size to 34 PSRs (34ncMF), which was still able to predict outcome (p & lt;0.001). Predictive accuracy of 39ncMF was significantly higher than 34gMF (96.4% vs. 70.8%, p & lt;0.001). However, predictive accuracy of the former was comparable to the non-redundant 34ncMF (96.7%, p=0.54). When the locked signatures were applied to the validation set, the 34gMF, 39ncMF and abbreviated 34ncMF were able to significantly predict outcomes (p=0.022, 0.006, 0.012, respectively). Analysis of biological processes using the coding 34gMF signature showed enrichment for functions associated with skeletal and muscular development and associated disorders, and over-representation of pathways associated with calcium and actin cytokeleton signaling in skeletal muscles. Similar analysis of non-coding signatures revealed enrichment for cellular assembly, cell cycle, apoptosis and cancer-associated functions and p53 signaling. Conclusions: A concise non-coding RNA meta-feature was able to better predict outcome in IR-RMS than a coding gene meta-feature, where most standard clinical prognosticators failed. The prognostic value of these meta-features was independently validated in patients with IR and non-IR RMS. These observations point to the possible role of non-coding transcripts in regulating and determining RMS biology and aggressiveness, and their potential to serve as novel prognostic indicators. Citation Format: Anirban P. Mitra, Sheetal A. Mitra, Jonathan D. Buckley, Philipp Kapranov, James R. Anderson, Stephen X. Skapek, Douglas S. Hawkins, Timothy J. Triche. Discovery and validation of novel prognostic genomic signatures in rhabdomyosarcoma. [abstract]. In: Proceedings of the AACR Special Conference on Pediatric Cancer at the Crossroads: Translating Discovery into Improved Outcomes; Nov 3-6, 2013; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2013;74(20 Suppl):Abstract nr A16.
Type of Medium:
Online Resource
ISSN:
0008-5472
,
1538-7445
DOI:
10.1158/1538-7445.PEDCAN-A16
Language:
English
Publisher:
American Association for Cancer Research (AACR)
Publication Date:
2014
detail.hit.zdb_id:
2036785-5
detail.hit.zdb_id:
1432-1
detail.hit.zdb_id:
410466-3
Permalink
